Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E.
Other stock markets
 15:05:30 2024-05-21 EDT 		5-day change 1st Jan Change
3.94 CAD -1.50% Intraday chart for Eupraxia Pharmaceuticals Inc. -1.75% -26.63%
05-14 Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 MT
05-08 Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board
MT
Top Premarket Decliners
MT
Eupraxia Pharmaceuticals Inc. Brief: Begins Trading on Nasdaq Today
MT
Eupraxia Pharmaceuticals Inc. Brief: Says to Begin Trading on Nasdaq on April 5, 2024
MT
Eupraxia Pharmaceuticals Inc. Brief: Says incurred a net loss of US$10.6 million for Q4, versus $7.8 million for the three months ended December 31, 2022
MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Toronto Stocks Edge Forward; Shares of Altius Minerals Rise on 4Q Revenue Beat
DJ
Update on Eupraxia Pharmaceuticals Announcing Updated "Positive" Clinical Data in EP-104GI RESOLVE Trial for Treatment of Eosinophilic Esophagitis
MT
Eupraxia Pharmaceuticals Announcing Updated "Positive" Clinical Data in EP-104GI RESOLVE Trial for Treatment of Eosinophilic Esophagitis
MT
Eupraxia Pharmaceuticals Inc. Brief: Announcing Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
MT
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
CI
Eupraxia Pharmaceuticals Initiated Phase 3 Development Program for EP-104IAR
MT
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR
CI
Eupraxia Pharmaceuticals Announces "Positive" Data from MRI Exploratory Sub-Study in Phase 2 Springboard Trial
MT
Eupraxia Pharmaceuticals Inc. Brief: Announcinh "Positive" Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating Safety and Efficacy of EP-104IAR for Treatment of Osteoarthritis of the Knee
MT
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee
CI
Eupraxia Pharmaceuticals Announces "Positive" Clinical Data in EP-104GI RESOLVE Trial
MT
Eupraxia Pharmaceuticals Inc. Announces Positive Clinical Data in EP-104GI RESOLVE Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. News Eupraxia Pharmaceuticals Inc.
  5. Highlights
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW